BGNE Stock Overview
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BGNE from our risk checks.
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$183.13 |
| 52 Week High | US$280.62 |
| 52 Week Low | US$156.56 |
| Beta | 0.63 |
| 1 Month Change | -1.86% |
| 3 Month Change | -11.77% |
| 1 Year Change | -4.43% |
| 3 Year Change | -19.33% |
| 5 Year Change | 24.44% |
| Change since IPO | 546.65% |
Recent News & Updates
Recent updates
Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?
Dec 07BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential
Oct 13EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa
Sep 16BeiGene, McKesson team up to develop data, tools for US community oncology care
Aug 15Novartis/BeiGene's tislelizumab matches Bayer's Nexavar in survival benefit for liver cancer patients in trial
Aug 09FDA defers action on Novartis/BeiGene's tislelizumab for esophagus cancer citing inspection woes
Jul 14BeiGene in pact with InnoRNA to develop messenger RNA-based therapies
Jul 06Health Check: How Prudently Does BeiGene (NASDAQ:BGNE) Use Debt?
Jun 30Shareholder Returns
| BGNE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 0.5% | 0.09% |
| 1Y | -4.4% | -8.9% | 10.4% |
Return vs Industry: BGNE exceeded the US Biotechs industry which returned -7.1% over the past year.
Return vs Market: BGNE underperformed the US Market which returned 13.3% over the past year.
Price Volatility
| BGNE volatility | |
|---|---|
| BGNE Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BGNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BGNE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10,000 | John Oyler | https://www.beigene.com |
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology.
BeiGene, Ltd. Fundamentals Summary
| BGNE fundamental statistics | |
|---|---|
| Market Cap | US$19.24b |
| Earnings (TTM) | -US$959.49m |
| Revenue (TTM) | US$2.20b |
8.6x
P/S Ratio-19.9x
P/E RatioIs BGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGNE income statement (TTM) | |
|---|---|
| Revenue | US$2.20b |
| Cost of Revenue | US$2.08b |
| Gross Profit | US$126.23m |
| Other Expenses | US$1.09b |
| Earnings | -US$959.49m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.22 |
| Gross Margin | 5.73% |
| Net Profit Margin | -43.52% |
| Debt/Equity Ratio | 14.1% |
How did BGNE perform over the long term?
See historical performance and comparison